Revenue
No reported data
PDS Biotechnology Corp (PDSB)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2014
2015
2016
2017
2018
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research & development | $19.0M | $22.6M | $27.8M | $29.4M | $11.3M | $7.9M | $6.1M | $830,744 | $34.3M | $24.8M | $17.8M | $8.5M | $4.5M |
| Operating expenses | $31.5M | $36.3M | $43.0M | $41.7M | $21.4M | $14.9M | $21.0M | $3.6M | $52.0M | $39.5M | $26.5M | $13.2M | $6.5M |
| Operating income | −$31.5M | −$36.3M | −$43.0M | −$41.7M | −$21.4M | −$14.9M | −$21.0M | −$3.6M | −$52.0M | −$39.5M | −$26.5M | −$13.2M | −$6.5M |
| EBITDAderived | — | — | — | — | — | −$14.9M | −$20.9M | −$3.6M | — | — | — | — | — |
| Net income | −$34.5M | −$37.6M | −$42.9M | −$40.9M | −$16.9M | −$14.8M | −$7.0M | −$3.8M | −$50.9M | −$38.8M | −$28.1M | −$12.2M | −$6.9M |
| Basic EPSper diluted share | -$0.74 | -$1.03 | -$1.39 | -$1.43 | -$0.66 | -$0.89 | -$1.44 | $1.15 | — | — | — | — | — |
| Diluted EPSper diluted share | -$0.74 | -$1.03 | -$1.39 | -$1.43 | -$0.66 | -$0.89 | -$1.44 | $1.15 | — | — | — | — | — |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Feb 28, 2025Form 4 | Freitag Gregory GeneDirector | BuyCommon Stock | 15.1K | $1.66 | $25.0K | 61.2K |
| Feb 28, 2025Form 4 | Freitag Gregory GeneDirector | BuyCommon Warrant · derivative | 15.1K | — | — | 15.1K |
| Feb 28, 2025Form 4 | Glover Stephen C.Director | BuyCommon Stock | 15.1K | $1.66 | $25.0K | 78.9K |
| Feb 28, 2025Form 4 | Glover Stephen C.Director | BuyCommon Warrant · derivative | 15.1K | — | — | 15.1K |